Patents Examined by Stephen Gucker
  • Delta subunit of human GABAA receptor
    Patent number: 7157249
    Abstract: The present invention relates to the cloning of novel cDNA sequences encoding the ?4 and ? receptor subunits of the human GABA A receptor; to stably co-transfected eukaryotic cell lines capable of expressing a human GABAA receptor, which receptor comprises at least one of the novel ?4 and ? receptor subunits; and to the use of such cell lines in screening for and designing medicaments which act upon the human GAGAA receptor.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 2, 2007
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Paul John Whiting
  • Pantropic neurotrophic factors
    Patent number: 7144983
    Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: December 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
  • Glial mitogenic factors, their preparation and use
    Patent number: 7135456
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells. The present invention is specifically directed to methods of using said polypeptides to induce myelination and to treat multiple sclerosis.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 14, 2006
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
    Patent number: 7119067
    Abstract: Nucleic acid molecules encoding human neuronal nicotinic acetylcholine receptor alpha and beta subunits, mammalian and amphibian cells containing the nucleic acid molecules, and methods for producing alpha and beta subunits are provided. In particular, nucleic acid molecules encoding ?6 subunits and molecules encoding ?3 subunits of human neuronal nicotinic acetylcholine receptors are provided. In addition, combinations of a plurality of subunits, such as one or more of ?1, ?2, ?3, ?4, ?5, ?6 and/or ?7 subunits in combination with one or more of ?3 subunits or such as one or more of ?2, ?3 and/or ?4 subunits in combination with an ?6 subunit are provided.
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: October 10, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Kathryn J. Elliott, Michael M. Harpold
  • Antibodies to prostate-specific membrane antigen
    Patent number: 7105159
    Abstract: This invention provides purified antibodies to the outer membrane domain of prostate-specific membrane (PSM) antigen, compositions of matter comprising PSM antigen antibodies conjugated to a radioisotope or a toxin, and a method of imaging prostate cancer by using PSM antigen antibodies.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 12, 2006
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
  • Recombinant human alpha-fetoprotein as a cell proliferative agent
    Patent number: 7101837
    Abstract: A method of promoting bone marrow cell proliferation in a mammal by administering unglycosylated recombinant human alpha-fetoprotein is disclosed.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: September 5, 2006
    Assignee: Martinex R & D Inc.
    Inventor: Robert A. Murgita
  • Glial mitogenic factors, their preparation and use
    Patent number: 7094749
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: August 22, 2006
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
  • Protein 68075 and its use for regenerating nerve cell processes
    Patent number: 7091329
    Abstract: Purified human 68075, or a purified protein comprising at least a portion of the endogenous human 68075, is active in promoting regeneration of a central or peripheral neuron.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: August 15, 2006
    Inventor: Stuart A. Lipton
  • FAP48-interacting proteins and use thereof
    Patent number: 7091173
    Abstract: Protein complexes are provided comprising FAP48 and one or more FAP48-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with FAP48 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: August 15, 2006
    Assignee: Myriad Genetics, Inc.
    Inventor: Daniel Cimbora
  • Regulation of intracellular glucocorticoid concentrations
    Patent number: 7087400
    Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: August 8, 2006
    Assignee: The University of Edinburgh
    Inventors: Brian Robert Walker, Christopher Richard Watkin Edwards, Jonathan Robert Seckl
  • Prostate-specific membrane antigen
    Patent number: 7070782
    Abstract: The invention provides a purified prostate-specific membrane antigen.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 4, 2006
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
  • Antimicrobial polypeptides and methods of use
    Patent number: 7067125
    Abstract: Antimicrobial compounds and compositions and uses thereof, including the treatment and prevention of bacterial infections are described. The compounds and compositions include lantibiotic polypeptides and the nucleic acid sequences encoding the polypeptides. The compounds and compositions are useful as antimicrobials in antibiotic pharmaceutical preparation and as an antimicrobial or antiseptic dentifrice.
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: June 27, 2006
    Assignee: University of Florida Research Foundation
    Inventor: Jeffrey Daniel Hillman
  • Anti-human VEGF receptor FLT-1 monoclonal antibody
    Patent number: 7052693
    Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: May 30, 2006
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Kenya Shitara, Mikito Ito, Nobuo Hanai, Yoko Kawada, Kazuyasu Nakamura, Masabumi Shibuya
  • G? protein variants and their use in the analysis and discovery of agonists and antagonists of chemosensory receptors
    Patent number: 7041457
    Abstract: The invention provides a series of G?q protein variants that functionally couple to sensory cell receptors such as taste GPCRs (TRs) and olfactory GPCRs (ORs) in an overly promiscuous manner. According to the invention, the functional coupling can be determined, for example, by measuring changes in intracellular IP3, or calcium. In a particular embodiment, the G?q protein variants can be expressed in mammalian cell lines or Xenopus oocytes, and then evaluated using calcium fluorescence imaging and electrophysiological recording.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: May 9, 2006
    Assignee: Senomyx, Inc.
    Inventors: Yong Yao, Hong Xu
  • C3b/C4b Complement Receptor-like molecules and uses thereof
    Patent number: 7041796
    Abstract: Novel C3b/C4b CR-like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing C3b/C4b CR-like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with C3b/C4b CR-like polypeptides.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: May 9, 2006
    Assignee: Amgen Inc.
    Inventors: Andrew A. Welcher, Gary S. Elliott
  • Prostate-specific membrane antigen and uses thereof
    Patent number: 7037647
    Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM?) antigen. This invention provides an isolated nucleic acid molecule encoding a prostate-specific membrane antigen promoter. This invention provides a method of detecting hematogenous micrometastic tumor cells of a subject, and determining prostate cancer progression in a subject.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: May 2, 2006
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
  • Treatment of eclampsia and preeclampsia
    Patent number: 7030083
    Abstract: The invention concerns the prevention and treatment of endothelial injury and the injury of tissues containing injured blood vessels by administration of angiogenic factors, such as vascular endothelial cell growth factor (VEGF).
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: April 18, 2006
    Assignees: University of Washington, Scios, Inc.
    Inventors: George F. Schreiner, Richard J. Johnson
  • ?-amyloid peptide-binding proteins and polynucleotides encoding the same
    Patent number: 7005295
    Abstract: Novel proteins which bind human ?-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: February 28, 2006
    Assignee: Wyeth
    Inventors: Bradley A. Ozenberger, Jonathan A. Bard, Eileen M. Kajkowski, Jack S. Jacobsen, Stephen G. Walker, Heidi Sofia
  • Human semaphorin proteins and polynucleotides encoding the same
    Patent number: 7001763
    Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: February 21, 2006
    Assignee: Lexicon Genetics Incorporated
    Inventors: D. Wade Walke, John Scoville
  • Anti-human VEGF receptor Flt-1 monoclonal antibody
    Patent number: 6986890
    Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: January 17, 2006
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Kenya Shitara, Mikito Ito, Nobuo Hanai, Yoko Kawada, Kazuyasu Nakamura, Masabumi Shibuya